Impact of TET2 gene mutations on the prognosis of patients with diffuse large B-cell lymphoma
Objective To observe the TET2 gene mutations in patients with diffuse large B-cell lymphoma(DLBCL),and to investigate its impact on the prognosis of DLBCL patients.Methods From January 2019 to December 2021,145 patients with initially diagnosed DLBCL in Henan Cancer Hospital underwent next-generation sequencing to assess mutations in TET2 gene,and were classified into the mutation group(n=35)and the no-mutation group(n=110)based on TET2 mutation status.Propensity score matching was performed to compare the baseline clinical data including age,Lugano stage,and International Prognostic Index(IPI)score before and after matching between two groups.Patients were followed for 1 to 3 years to record the survival in two groups.Kaplan-Meier survival curves were generated to compare the rates of overall survival(OS)and progression-free survival(PFS).Multivariate Cox regression analysis was conducted to identify factors influencing disease progression of DLBCL patients.Results Before propensity score matching,the mutation group exhibited higher proportions of patients aged ≥60 years(57.14％)and with IPI score of 3-5(54.29％)compared to the no-mutation group(32.73％,27.27％)(x2=6.677,P=0.010;x2=8.660,P=0.003).After propensity score matching,the proportions of patients aged ≥60 years and with IPI score of 3-5 did not differ significantly between the mutation group(50.00％,46.67％)and the no-mutation group(56.67％,33.33％)(x2=0.268,P=0.605;x2=1.111,P=0.292).The follow-up duration was 25(18,34)months.The median PFS of the mutation group was 20 months,while the median OS was 26 months.For the no-mutation group,the median PFS was 30 months,and the median OS had not been reached(no endpoint events developed at the time of the latest follow-up).The 3-year PFS rate and 3-year OS rate were significantly lower in the mutation group(17.3％,25.9％)than those in the no-mutation group(37.2％,50.6％)(x2=5.046,P=0.025;x2=5.061,P=0.024).TET2 gene mutation was an influencing factor of disease progression in DLBCL patients(HR=2.396,95％CI:1.065-5.388,P=0.035).Conclusion DLBCL patients with TET2 gene mutation are at an increased risk of disease progression.
diffuse large B-cell lymphomaTET2 genemutationprognosis
NETL
NSTL
万方数据
